| Original language | English (US) |
|---|---|
| Pages (from-to) | 1469-1472 |
| Number of pages | 4 |
| Journal | Kidney International Reports |
| Volume | 8 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2023 |
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Kidney International Reports, Vol. 8, No. 7, 07.2023, p. 1469-1472.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant
AU - Genena, Kareem M.
AU - Sas, David J.
AU - Milliner, Dawn S.
AU - Lieske, John C.
N1 - Funding Information: This work is partly supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases ( DK133171 ). In addition, this work was also funded by the Rare Kidney Stone Consortium (U54DK83908), which is part of Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences. This consortium is funded through collaboration between National Center for Advancing Translational Sciences, and the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported by funds from the Oxalosis and Hyperoxaluria Foundation, and Mayo Foundation. Those funding the study had no role in study design, analysis, reporting, or decision to submit the manuscript for publication. Funding Information: DSM has received consulting fees from OxThera, Dicerna, Allena, Alnylam, and Synlogic; and grant support from the NIDDK, OxThera, Dicerna, and Alnylam. JCL receives consulting fees from the American Board of Internal Medicine, Alnylam, Federation Bio, OxThera, Precision Biosciences, Cantero/Bridgebio, Dicerna, Synlogic, Orfan, Intellia, Mirium, Biomarin, and Novobiome; and grant support from Alnylam, Allena, Retrophin, Synlogic, Novobiome, OxThera, NIDDK, and Dicerna. DJS has received grant funding from Alnylam and Dicerna, as well as consulting fees from Advicenne. KMG declared no conflict of interest.
PY - 2023/7
Y1 - 2023/7
UR - http://www.scopus.com/inward/record.url?scp=85152553954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152553954&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2023.03.013
DO - 10.1016/j.ekir.2023.03.013
M3 - Article
AN - SCOPUS:85152553954
SN - 2468-0249
VL - 8
SP - 1469
EP - 1472
JO - Kidney International Reports
JF - Kidney International Reports
IS - 7
ER -